Atherogenic Coefficient

The atherogenic coefficient is calculated by dividing total cholesterol (TC) by HDL cholesterol (HDL-C). This ratio turns two standard lipid panel numbers into a single, clinically meaningful marker of balance: how much cholesterol is being carried by all lipoproteins in your blood (the numerator) relative to your “protective” HDL cholesterol (the denominator). For example, a ratio of 4.0 means your total cholesterol is four times your HDL cholesterol. Total cholesterol includes cholesterol carried by multiple particle types — LDL, VLDL, IDL, and HDL — while HDL represents particles that help remove excess cholesterol from tissues (including artery walls) and return it to the liver through reverse cholesterol transport. In practical terms, the ratio estimates whether potentially harmful cholesterol-carrying particles dominate over HDL’s protective functions. A higher ratio suggests a less favourable balance (more atherogenic burden relative to protection), while a lower ratio suggests a healthier balance. Because it relies only on total cholesterol and HDL cholesterol, it requires no specialised testing beyond a standard lipid panel, making it accessible, cost-effective, and easy to track over time. This marker has been validated across populations and age groups, although its predictive value may lessen somewhat in adults over ~65 years.

The atherogenic coefficient (TC/HDL-C ratio) is consistently described as a stronger predictor of cardiovascular disease risk than LDL cholesterol alone, and in many studies it outperforms single lipid markers for identifying risk of heart attack, stroke, coronary artery disease, and cardiovascular death. One reason is that the ratio can detect “residual” risk even when traditional markers look acceptable. Research describes “discordance,” where a person’s TC/HDL-C ratio is elevated despite LDL-C or non-HDL-C being below the median. In these discordant profiles, cardiovascular risk is still higher—highlighting that the ratio can capture risk that isn’t obvious when you look at LDL-C alone.

Mechanistically, an elevated TC/HDL-C ratio reflects multiple atherogenic processes at once. A higher ratio is often seen alongside atherogenic dyslipidemia — a pattern that tends to include higher triglycerides, lower HDL, and a predominance of small, dense LDL particles (which more easily penetrate artery walls, are more prone to oxidation, and promote inflammatory plaque formation). The ratio also indirectly reflects the contribution of triglyceride-rich lipoproteins (VLDL and remnants), which can carry substantial cholesterol per particle and contribute to plaque development. At the same time, a higher ratio implies that reverse cholesterol transport (HDL’s cholesterol-removal role) is not keeping pace with the overall cholesterol burden. HDL is not just “good cholesterol” by name—its particles are described as having anti-inflammatory, antioxidant, and cholesterol-efflux (cholesterol removal) functions that help protect arteries.

Clinically, the TC/HDL-C ratio is closely linked with broader metabolic health. Elevated ratios are strongly associated with metabolic syndrome, insulin resistance, type 2 diabetes, obesity, and systemic inflammation (e.g., hs-CRP), and the ratio correlates with blood pressure and abdominal (visceral) adiposity. Importantly, studies using serial imaging show that higher TC/HDL-C ratios are associated with faster plaque accumulation and progression, not just the presence of disease. Risk appears graded and continuous (higher ratio → higher risk, progressively). While cutoffs vary by population, the guide notes general interpretation bands: below ~3.0–3.5 tends to reflect lower risk; ~3.5–5.0 moderate risk; and above ~5.0 substantially higher risk requiring more intensive intervention aligned with an individual’s overall risk profile.

Dietary factors

Because the ratio depends on total cholesterol and HDL, diet shifts that raise total cholesterol or lower HDL tend to worsen the ratio. Higher intake of saturated fats (e.g., fatty red meat, processed meats, full-fat dairy, butter/cream; also tropical oils noted in the guide) generally increases total cholesterol more than HDL, raising the ratio. Trans fats (partially hydrogenated oils, many commercial baked goods, fried fast foods, shortening) are described as especially harmful: they raise atherogenic cholesterol while lowering HDL, producing a strong negative effect on the TC/HDL-C ratio. Refined carbohydrates and added sugars (white bread/rice/pasta, pastries, sugary drinks, sweets) can raise triglycerides and VLDL (part of total cholesterol) and often reduce HDL—particularly in insulin resistance—thereby increasing the ratio.

Conversely, replacing saturated/trans fats with cis-unsaturated fats improves the ratio more effectively than replacing saturated fat with carbohydrate. Diets rich in monounsaturated fats (extra virgin olive oil, avocados, nuts, seeds) improve lipid balance without harming HDL. Polyunsaturated fats, including omega-3 sources (fatty fish; walnuts, flax, chia), can support a more favourable lipid pattern — especially in people with higher triglycerides — contributing to ratio improvement. Choosing lower-glycaemic, minimally processed carbohydrates (whole grains, legumes, non-starchy vegetables, most whole fruits) is also described as more favourable than refined carbohydrates due to smaller impacts on insulin and triglyceride production.

Lifestyle factors
Regular physical activity improves the ratio mainly by raising HDL and modestly improving total cholesterol and triglycerides. The guide cites typical targets of ~150–300 minutes/week of moderate-to-vigorous aerobic activity, with greater activity volumes generally producing larger benefits; consistency across the week appears more effective than concentrating activity into one or two days.

Body weight and abdominal adiposity are among the strongest determinants. Visceral obesity is linked to higher ratios via insulin resistance, increased VLDL production, reduced triglyceride clearance, and adverse HDL effects. Weight loss produces dose-dependent improvements: as weight decreases, triglycerides tend to decrease and HDL tends to increase, improving the ratio — especially once weight stabilises.

Smoking worsens the ratio largely by lowering HDL, and cessation improves HDL and the ratio relatively quickly, even if modest weight gain occurs after quitting.

Related biomarkers and conditions
The ratio moves with the broader cardiometabolic profile: triglycerides, HDL-C, LDL-C, and markers of insulin resistance/glycaemia (glucose, HbA1c) as well as inflammatory markers such as hs-CRP often track alongside higher ratios.

Micronutrients and bioactive compounds
The guide notes evidence that certain interventions can improve lipid parameters that influence the ratio: omega-3 (EPA/DHA) at therapeutic doses (noted as 2–4 g/day) lowers triglycerides and may modestly raise HDL; plant sterols/stanols (noted as 2–3 g/day) reduce total and LDL cholesterol; and viscous soluble fibre (oats, barley, psyllium, beans, some vegetables) lowers total and LDL cholesterol. Some micronutrients/bioactives (e.g., anthocyanins, folic acid, magnesium, polyphenol-rich extracts) are noted to improve lipid profiles in controlled studies, though effects vary.

1. Elshazly MB, Nicholls SJ, Nissen SE, et al. Implications of total to high-density lipoprotein cholesterol ratio discordance with alternative lipid parameters for coronary atheroma progression and cardiovascular events. The American Journal of Cardiology. 2016;118(5):647-655. doi:10.1016/j.amjcard.2016.06.021.

2. Quispe R, Elshazly MB, Zhao D, et al. Total cholesterol/HDL-cholesterol ratio discordance with LDL-cholesterol and non-HDL-cholesterol and incidence of atherosclerotic cardiovascular disease in primary prevention: The ARIC study. European Journal of Preventive Cardiology. 2020;27(15):1597-1605. doi:10.1177/2047487319862401.

3. Arsenault BJ, Rana JS, Stroes ES, et al. Beyond low-density lipoprotein cholesterol: Respective contributions of non-high-density lipoprotein cholesterol levels, triglycerides, and the total cholesterol/high-density lipoprotein cholesterol ratio to coronary heart disease risk in apparently healthy men and women. Journal of the American College of Cardiology. 2009;55(1):35-41. doi:10.1016/j.jacc.2009.07.057.

4. Nam BH, Kannel WB, D'Agostino RB. Search for an optimal atherogenic lipid risk profile: From the Framingham study. The American Journal of Cardiology. 2006;97(3):372-375. doi:10.1016/j.amjcard.2005.08.055.

5. Ramjee V, Sperling LS, Jacobson TA. Non-high-density lipoprotein cholesterol versus apolipoprotein B in cardiovascular risk stratification: Do the math. Journal of the American College of Cardiology. 2011;58(5):457-463. doi:10.1016/j.jacc.2011.05.009.

6. Gaggini M, Gorini F, Vassalle C. Lipids in atherosclerosis: Pathophysiology and the role of calculated lipid indices in assessing cardiovascular risk in patients with hyperlipidemia. International Journal of Molecular Sciences. 2022;24(1):75. doi:10.3390/ijms24010075.

7. Castañer O, Pintó X, Subirana I, et al. Remnant cholesterol, not LDL cholesterol, is associated with incident cardiovascular disease. Journal of the American College of Cardiology. 2020;76(23):2712-2724. doi:10.1016/j.jacc.2020.10.008.

8. Sperling LS, Mechanick JI, Neeland IJ, et al. The CardioMetabolic Health Alliance: Working toward a new care model for the metabolic syndrome. Journal of the American College of Cardiology. 2015;66(9):1050-1067. doi:10.1016/j.jacc.2015.06.1328.

9. Mechanick JI, Farkouh ME, Newman JD, Garvey WT. Cardiometabolic-based chronic disease, adiposity and dysglycemia drivers: JACC state-of-the-art review. Journal of the American College of Cardiology. 2020;75(5):525-538. doi:10.1016/j.jacc.2019.11.044.

10. Rosenzweig JL, Bakris GL, Berglund LF, et al. Primary prevention of ASCVD and T2DM in patients at metabolic risk: An Endocrine Society clinical practice guideline. The Journal of Clinical Endocrinology and Metabolism. 2019;104(9):3939-3985. doi:10.1210/jc.2019-01338.

11. Aboonabi A, Meyer RR, Singh I. The association between metabolic syndrome components and the development of atherosclerosis. Journal of Human Hypertension. 2019;33(12):844-855. doi:10.1038/s41371-019-0273-0.

12. Linn S, Fulwood R, Carroll M, et al. Serum total cholesterol: HDL cholesterol ratios in US white and black adults by selected demographic and socioeconomic variables (HANES II). American Journal of Public Health. 1991;81(8):1038-1043. doi:10.2105/ajph.81.8.1038.

13. Kim S, Shin MJ, Krauss RM. Dietary management of atherogenic dyslipidemia. Current Atherosclerosis Reports. 2025;27(1):93. doi:10.1007/s11883-025-01335-6.

14. Mensink RP, Zock PL, Kester AD, Katan MB. Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: A meta-analysis of 60 controlled trials. The American Journal of Clinical Nutrition. 2003;77(5):1146-1155. doi:10.1093/ajcn/77.5.1146.

15. Natarajan P, Ray KK, Cannon CP. High-density lipoprotein and coronary heart disease: Current and future therapies. Journal of the American College of Cardiology. 2010;55(13):1283-1299. doi:10.1016/j.jacc.2010.01.008.

16. Mente A, Dehghan M, Rangarajan S, et al. Association of dietary nutrients with blood lipids and blood pressure in 18 countries: A cross-sectional analysis from the PURE study. The Lancet Diabetes & Endocrinology. 2017;5(10):774-787. doi:10.1016/S2213-8587(17)30283-8.

17. Singh IM, Shishehbor MH, Ansell BJ. High-density lipoprotein as a therapeutic target: A systematic review. JAMA. 2007;298(7):786-798. doi:10.1001/jama.298.7.786.

18. Diabetes Care. 10. Cardiovascular disease and risk management: Standards of care in diabetes—2025. Diabetes Care. 2025;48(Suppl 1):S207-S238. doi:10.2337/dc25-S010.

19. Newman CB, Blaha MJ, Boord JB, et al. Lipid management in patients with endocrine disorders: An Endocrine Society clinical practice guideline. The Journal of Clinical Endocrinology and Metabolism. 2020;105(12):dgaa674. doi:10.1210/clinem/dgaa674.

20. Berisha H, Hattab R, Comi L, et al. Nutrition and lifestyle interventions in managing dyslipidemia and cardiometabolic risk. Nutrients. 2025;17(5):776. doi:10.3390/nu17050776.

21. Amani-Beni R, Darouei B, Mohammadifard N, et al. Exploring the association between healthy lifestyle score and atherogenic indices in a general population of Iranian adults. Lipids in Health and Disease. 2025;24(1):206. doi:10.1186/s12944-025-02631-5.

22. Jacobson TA, Maki KC, Orringer CE, et al. National Lipid Association recommendations for patient-centered management of dyslipidemia: Part 2. Journal of Clinical Lipidology. 2015;9(6 Suppl):S1-S122.e1. doi:10.1016/j.jacl.2015.09.002.

23. Hasan B, Nayfeh T, Alzuabi M, et al. Weight loss and serum lipids in overweight and obese adults: A systematic review and meta-analysis. The Journal of Clinical Endocrinology and Metabolism. 2020;105(12):dgaa673. doi:10.1210/clinem/dgaa673.

24. Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults. Journal of the American College of Cardiology. 2014;63(25 Pt B):2985-3023. doi:10.1016/j.jacc.2013.11.004.

25. Bays HE, Kirkpatrick CF, Maki KC, et al. Obesity, dyslipidemia, and cardiovascular disease: A joint expert review from the Obesity Medicine Association and the National Lipid Association 2024. Journal of Clinical Lipidology. 2024;18(3):e320-e350. doi:10.1016/j.jacl.2024.04.001.

26. Stadler JT, Marsche G. Obesity-related changes in high-density lipoprotein metabolism and function. International Journal of Molecular Sciences. 2020;21(23):E8985. doi:10.3390/ijms21238985.

27. Dattilo AM, Kris-Etherton PM. Effects of weight reduction on blood lipids and lipoproteins: A meta-analysis. The American Journal of Clinical Nutrition. 1992;56(2):320-328. doi:10.1093/ajcn/56.2.320.

28. Colsoul ML, Goderniaux N, Onorati S, et al. Changes in biomarkers of endothelial function, oxidative stress, inflammation and lipids after smoking cessation: A cohort study. European Journal of Clinical Investigation. 2023;53(8):e13996. doi:10.1111/eci.13996.

29. Gepner AD, Piper ME, Johnson HM, et al. Effects of smoking and smoking cessation on lipids and lipoproteins: Outcomes from a randomized clinical trial. American Heart Journal. 2011;161(1):145-151. doi:10.1016/j.ahj.2010.09.023.

30. Kalkhoran S, Benowitz NL, Rigotti NA. Reprint of: Prevention and treatment of tobacco use: JACC health promotion series. Journal of the American College of Cardiology. 2018;72(23 Pt B):2964-2979. doi:10.1016/j.jacc.2018.10.020.

31. Barone Gibbs B, Hivert MF, Jerome GJ, et al. Physical activity as a critical component of first-line treatment for elevated blood pressure or cholesterol: A scientific statement from the American Heart Association. Hypertension. 2021;78(2):e26-e37. doi:10.1161/HYP.0000000000000196.

32. Kalkhoran S, Benowitz NL, Rigotti NA. Prevention and treatment of tobacco use: JACC health promotion series. Journal of the American College of Cardiology. 2018;72(9):1030-1045. doi:10.1016/j.jacc.2018.06.036.

33. Elbadawi NS, Sobih MH, Soliman MZ, et al. Association between atherogenic dyslipidemia and subclinical myocardial injury in the general population. Journal of Clinical Medicine. 2024;13(16):4946. doi:10.3390/jcm13164946.

34. An P, Wan S, Luo Y, et al. Micronutrient supplementation to reduce cardiovascular risk. Journal of the American College of Cardiology. 2022;80(24):2269-2285. doi:10.1016/j.jacc.2022.09.048.

35. Ge Q, Yan Y, Luo Y, et al. Dietary supplements: Clinical cholesterol-lowering efficacy and potential mechanisms of action. International Journal of Food Sciences and Nutrition. 2024;75(4):349-368. doi:10.1080/09637486.2024.2342301.

36. Kim DS, Burt AA, Ranchalis JE, et al. Effects of dietary components on high-density lipoprotein measures in a cohort of 1,566 participants. Nutrition & Metabolism. 2014;11(1):44. doi:10.1186/1743-7075-11-44.